Kirk CJ - Search Results

1

Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.

Zang Y, Kirk CJ, Johnson DE. Zang Y, et al. Among authors: kirk cj. Cancer Biol Ther. 2014 Sep;15(9):1142-52. doi: 10.4161/cbt.29452. Epub 2014 Jun 10. Cancer Biol Ther. 2014. PMID: 24915039 Free PMC article.

2

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Zang Y, et al. Among authors: kirk cj. Clin Cancer Res. 2012 Oct 15;18(20):5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28. Clin Cancer Res. 2012. PMID: 22929803 Free PMC article.

3

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Zang Y, et al. Among authors: kirk cj. Autophagy. 2012 Dec;8(12):1873-4. doi: 10.4161/auto.22185. Epub 2012 Sep 20. Autophagy. 2012. PMID: 22995770 Free PMC article.

4

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ. Arastu-Kapur S, et al. Among authors: kirk cj. Clin Cancer Res. 2011 May 1;17(9):2734-43. doi: 10.1158/1078-0432.CCR-10-1950. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364033

5

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Demo SD, et al. Among authors: kirk cj. Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086. Cancer Res. 2007. PMID: 17616698

6

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ. Kirk CJ. Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Semin Hematol. 2012. PMID: 22726543 Review.

7

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.

Wang J, Fang Y, Fan RA, Kirk CJ. Wang J, et al. Among authors: kirk cj. Int J Mol Sci. 2021 Oct 27;22(21):11595. doi: 10.3390/ijms222111595. Int J Mol Sci. 2021. PMID: 34769030 Free PMC article. Review.

8

Molecular mechanisms of bortezomib resistant adenocarcinoma cells.

Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ. Suzuki E, et al. Among authors: kirk cj. PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216088 Free PMC article.

9

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR. Wang Z, et al. Drug Metab Dispos. 2013 Jan;41(1):230-7. doi: 10.1124/dmd.112.047662. Epub 2012 Nov 1. Drug Metab Dispos. 2013. PMID: 23118326 Clinical Trial.

10

Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.

Niewerth D, van Meerloo J, Jansen G, Assaraf YG, Hendrickx TC, Kirk CJ, Anderl JL, Zweegman S, Kaspers GJ, Cloos J. Niewerth D, et al. Among authors: kirk cj. Biochem Pharmacol. 2014 May 1;89(1):43-51. doi: 10.1016/j.bcp.2014.02.005. Epub 2014 Feb 16. Biochem Pharmacol. 2014. PMID: 24552657

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

203 results

Search Page